ArticleJournal of ovarian research2025
Identification of parthanatos-related molecular subtypes and development of prognostic risk models in ovarian cancer based on multi-omics analysis.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Cell death analysis of inducible, titratable neurodegenerative disease models in zebrafish and human stem cell-derived retinal organoids.Disease models & mechanisms · 2026Article
- A machine learning-based basement membrane gene signature model for predicting ovarian cancer survival.Translational cancer research · 2026Article
- Regulated cell death in ovarian cancer: molecular mechanisms and therapeutic targets.Frontiers in cell and developmental biology · 2026Review
- Identification and Experimental Verification Reveal SLC2A3 Associated With Prognosis and Immune Infiltration in Colon Adenocarcinoma.Mediators of inflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Ovarian cancer (OC) remains the most lethal gynecologic malignancy due to late-stage diagnosis, high recurrence rates, and chemoresistance. Parthanatos, a distinct caspase-independent form of programmed cell death mediated by poly (ADP-ribose) (PAR), plays a critical role in DNA damage response and tumor progression. In this study, we identified parthanatos-related genes (PRG) associated with OC prognosis based on integrated analyses of TCGA and GEO datasets, and developed a PRG-based risk model with significant prognostic value. Immune infiltration analysis and single-cell RNA sequencing revealed that high-risk patients exhibited a more immunosuppressive tumor microenvironment. Drug sensitivity profiling and clinical subgroup analyses further supported the model's clinical applicability. Among the screened PRG, TGFBI was selected for experimental validation, and in vitro assays including qRT-PCR, western blotting, colony formation, and Transwell migration demonstrated its role in promoting OC cell proliferation, invasion, and clonogenicity. These findings underscore the prognostic and biological significance of parthanatos in OC and suggest that targeting key PRG such as TGFBI may offer novel therapeutic strategies to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.